HIV drug repurposed to fight muscle inflammation

NCT ID NCT07668505

Not yet recruiting Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tests whether Maraviroc, a drug currently used for HIV, can reduce muscle inflammation and improve function in adults with myositis that hasn't responded to standard treatments. Ten participants will take a daily 300mg tablet for 12 weeks and undergo muscle biopsies and function tests. The goal is to see if the drug can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Maraviroc (Selzentry, Celsentri)
What this could lead to: If it works, this could offer a new treatment option for people with myositis who haven't responded to standard therapies.
What could go wrong: This is a very small, early-phase trial with only 10 participants and no placebo group, so results may not be reliable or apply to everyone. The drug may not improve symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic inflammatory myopathy juvenile dermatomyositis myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOSITIS

Contacts and locations

Locations

Prince of Wales Hospital

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.